Signal
PTC withdraws translarna FDA application after regulator feedback
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-02-13 10:55 UTCUpdated 2026-02-13 15:11 UTC
rss
fdaregulatorydrug_developmentrare_diseaseneuromuscular
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
PTC Therapeutics withdrew its FDA application for Translarna after receiving feedback from the agency on its filing. The application related to Translarna in nonsense mutation Duchenne muscular dystrophy, according to trade reports.
Entities
Translarna
Score total
0.99
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- PTC disclosed the withdrawal following FDA feedback on the filing
- Multiple trade outlets reported the decision in the same news cycle
Why it matters
- Resets the near-term U.S. regulatory timeline for Translarna
- Signals FDA feedback can materially alter filing strategy and timing
- Adds uncertainty on when/if an FDA review cycle will proceed
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- PTC Therapeutics withdrew its FDA application for Translarna after receiving feedback from the regulator on its filing.
- The withdrawn application concerned Translarna for nonsense mutation Duchenne muscular dystrophy.
How sources frame it
- Pharmaphorum: neutral
- Fierce Pharma: neutral
Two trade outlets report the same regulatory action; details beyond withdrawal/indication are not evidenced in the provided posts.
All evidence
All evidence
Late Thursday, PTC revealed that it withdrew its FDA application for Translarna in nonsense mutation Duchenne muscular dystrophy after receiving feedback on its filing from the ...
Fierce Pharma (All) · fiercepharma.com · 2026-02-13 15:11 UTC
PTC pulls file for Duchenne therapy on FDA feedback
pharmaphorum · pharmaphorum.com · 2026-02-13 10:55 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Pharma (All) (1)
- pharmaphorum (1)
Top origin domains (this list)
- fiercepharma.com (1)
- pharmaphorum.com (1)